BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 17761812)

  • 1. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.
    Williams RT; den Besten W; Sherr CJ
    Genes Dev; 2007 Sep; 21(18):2283-7. PubMed ID: 17761812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
    Williams RT; Roussel MF; Sherr CJ
    Proc Natl Acad Sci U S A; 2006 Apr; 103(17):6688-93. PubMed ID: 16618932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
    Williams RT; Sherr CJ
    Adv Exp Med Biol; 2007; 604():107-14. PubMed ID: 17695724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Boulos N; Mulder HL; Calabrese CR; Morrison JB; Rehg JE; Relling MV; Sherr CJ; Williams RT
    Blood; 2011 Mar; 117(13):3585-95. PubMed ID: 21263154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
    Pfeifer H; Wassmann B; Pavlova A; Wunderle L; Oldenburg J; Binckebanck A; Lange T; Hochhaus A; Wystub S; Brück P; Hoelzer D; Ottmann OG
    Blood; 2007 Jul; 110(2):727-34. PubMed ID: 17405907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
    Hofmann WK; Komor M; Wassmann B; Jones LC; Gschaidmeier H; Hoelzer D; Koeffler HP; Ottmann OG
    Blood; 2003 Jul; 102(2):659-61. PubMed ID: 12663457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib.
    Kumari A; Brendel C; Hochhaus A; Neubauer A; Burchert A
    Blood; 2012 Jan; 119(2):530-9. PubMed ID: 22101898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
    Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
    Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
    Mishra S; Zhang B; Groffen J; Heisterkamp N
    Leukemia; 2004 Jan; 18(1):23-8. PubMed ID: 14603339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
    Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
    Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study.
    Chang BH; Willis SG; Stork L; Hunger SP; Carroll WL; Camitta BM; Winick NJ; Druker BJ; Schultz KR
    Br J Haematol; 2012 May; 157(4):507-10. PubMed ID: 22299775
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
    Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
    Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
    Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
    Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion.
    Tachibana T; Numata A; Tanaka M; Motohashi K; Fujisawa S; Fujita H; Sakai R; Tomita N; Maruta A; Ishigatsubo Y; Kanamori H
    Leuk Lymphoma; 2011 Jul; 52(7):1376-9. PubMed ID: 21438838
    [No Abstract]   [Full Text] [Related]  

  • 17. High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.
    Young FM; Campbell A; Emo KL; Jansson J; Wang PY; Jordan CT; Mullen CA
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):622-30. PubMed ID: 18489987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
    Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
    Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
    Grammatico S; Elia L; Peluso AL; Pedace L; Matarazzo M; Vitale A; Rago A; Pane F; Foà R; Cimino G
    Leuk Res; 2009 Jul; 33(7):e73-4. PubMed ID: 19108887
    [No Abstract]   [Full Text] [Related]  

  • 20. The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities.
    Ottmann OG; Hoelzer D
    Hematol J; 2002; 3(1):2-6. PubMed ID: 11960387
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.